MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Enanta Pharmaceuticals Company Profile (NASDAQ:ENTA)

Consensus Ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $27.50 (12.75% upside)

Analysts' Ratings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Show:
DateFirmActionRatingPrice TargetActions
4/28/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016JPMorgan Chase & Co.Lower Price TargetOverweight$45.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016BarclaysBoost Price TargetUnderweight$16.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016Robert W. BairdReiterated RatingNeutral$36.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2015Leerink SwannLower Price TargetOutperform$42.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2015Deutsche BankInitiated CoverageBuy$42.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/24/2014FBR & Co.Reiterated RatingOutperform$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/15/2014Credit SuisseBoost Price TargetOutperform$43.00 -> $44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/28/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha